Your browser is no longer supported. Please, upgrade your browser.
Settings
AMGN [NASD]
Amgen Inc.
IndexS&P 500 P/E23.96 EPS (ttm)6.70 Insider Own0.20% Shs Outstand758.86M Perf Week-5.06%
Market Cap121.83B Forward P/E15.28 EPS next Y10.50 Insider Trans-1.94% Shs Float757.55M Perf Month1.56%
Income5.16B PEG2.16 EPS next Q2.11 Inst Own82.60% Short Float1.36% Perf Quarter2.46%
Sales20.06B P/S6.07 EPS this Y0.90% Inst Trans-0.64% Short Ratio2.95 Perf Half Y13.91%
Book/sh33.83 P/B4.75 EPS next Y12.80% ROA7.50% Target Price176.26 Perf Year36.28%
Cash/sh35.61 P/C4.51 EPS next 5Y11.10% ROE21.00% 52W Range106.12 - 172.36 Perf YTD1.33%
Dividend3.16 P/FCF21.37 EPS past 5Y8.20% ROI10.20% 52W High-6.85% Beta0.56
Dividend %1.97% Quick Ratio4.60 Sales past 5Y6.50% Gross Margin80.00% 52W Low51.29% ATR3.59
Employees17900 Current Ratio5.00 Sales Q/Q6.40% Oper. Margin34.70% RSI (14)49.81 Volatility2.68% 2.15%
OptionableYes Debt/Eq1.19 EPS Q/Q25.60% Profit Margin25.70% Rel Volume0.91 Prev Close160.62
ShortableYes LT Debt/Eq1.17 EarningsApr 21 AMC Payout35.90% Avg Volume3.50M Price160.55
Recom2.40 SMA200.24% SMA502.32% SMA20011.30% Volume3,145,000 Change-0.04%
Oct-29-14Reiterated Argus Buy $140 → $185
Oct-28-14Reiterated RBC Capital Mkts Outperform $150 → $165
Sep-08-14Reiterated RBC Capital Mkts Outperform $138 → $150
Aug-04-14Reiterated Argus Buy $135 → $140
Jul-30-14Reiterated RBC Capital Mkts Outperform $125 → $138
Jul-18-14Reiterated Deutsche Bank Buy $144 → $149
Apr-23-14Reiterated Oppenheimer Perform $121 → $122
Mar-21-14Reiterated Barclays Equal Weight $115 → $130
Jan-31-14Reiterated Argus Buy $130 → $135
Nov-20-13Reiterated Deutsche Bank Buy $138 → $142
Aug-29-13Reiterated UBS Buy $121 → $124
Aug-27-13Reiterated Barclays Overweight $105 → $115
Jul-31-13Reiterated Oppenheimer Perform $100 → $109
Apr-24-13Reiterated Deutsche Bank Buy $108 → $115
Apr-15-13Reiterated Barclays Equal Weight $90 → $105
Apr-08-13Reiterated RBC Capital Mkts Outperform $95 → $105
Jan-25-13Upgrade Argus Hold → Buy $96
Jan-24-13Reiterated UBS Buy $96 → $98
Sep-12-12Downgrade Robert W. Baird Outperform → Neutral $84
Sep-10-12Upgrade UBS Neutral → Buy $80 → $96
Mar-26-15 06:07PM  Final Glance: Biotechnology companies
04:17PM  Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer at noodls
04:01PM  Cancer Survivor Joan Lunden Named 2015 Honorary Breakaway From Cancer® Champion And Joins Nationwide Search For Ten Champions In The Fight Against Cancer PR Newswire
02:20PM  Midday Glance: Biotechnology companies
02:12PM  Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks at Forbes
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
10:34AM  Early Glance: Biotechnology companies
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Biogen, Prothena, Vertex, Gilead and Amgen - Press Releases
09:25AM  Kite Pharma (KITE) Posts Wider-Than-Expected Q4 Loss - Tale of the Tape
Mar-25-15 06:50PM  Trading the selloff: 8 stocks to buy at CNBC
05:20PM  Ligand Pharmaceuticals: Biotech's Jack Of All Trades at Investor's Business Daily
05:11PM  Dismal Data Drops Dow 300 Points, Nasdaq Crumbles as Biotech Tumbles at Barrons.com
05:00PM  Trading the selloff: 8 stocks to buy
05:00PM  Biotech in nice uptrend: Adami
03:22PM  The Genomic Portrait of a Nation at noodls
03:21PM  Worries Bubble About Biotech at Barrons.com
03:11PM  Amgen Releases A Giant Genetic Portrait Of A Nation -- And A Map Of The Future at Forbes
02:00PM  Amgens Iceland DNA Quest Scans Nations Genes for Disease Clues at Bloomberg
01:50PM  Amgen to appeal rejection of bid to block Novartis biosimilar drug Reuters
01:09PM  Biotechs' Surge Brings Lofty Valuations at The Wall Street Journal
11:50AM  Biotech's Rally Fuels Bubble Fears at The Wall Street Journal
10:28AM  Biotech Stock Roundup: Biogen Soars on Alzheimer's Data, Gilead HCV Drugs Label Update - Analyst Blog
10:21AM  Why These Could Be 2015's 10 Best Biotech Stocks at Investopedia
10:06AM  The PharmacyclicsAbbVie Merger: The Basics of Pharmacyclics
09:15AM  Major Biotech Is So-So for Short Sellers at 24/7 Wall St.
Mar-24-15 11:52PM  [$$] Biotechs Rally Fuels Bubble Fears at The Wall Street Journal
02:53PM  Johnson & Johnson May See EPS Drag Through 2018 at Barrons.com
10:10AM  Stock Market News for March 24, 2015 - Market News
07:36AM  10 Undervalued Stocks Insiders Are Buying at Barrons.com
Mar-23-15 06:12PM  Amgen Seeks Approval for PCSK9 Inhibitor Repatha in Japan - Analyst Blog
04:55PM  The Fibocall on Amgen Generating Long-Term Overbought Condition at TheStreet
04:22PM  How Lilly and Amgen Are Going in Opposite Directions at TheStreet
03:37PM  Signs of Froth in the Biotech Sector
02:58PM  11 Promising New Drugs Expected to Make Billions in Sales at TheStreet
02:18PM  Jim Cramer Digs Into Dozens of Charts, Finds 7 Pillars of Health Care Strength at TheStreet
12:50PM  Apple climbs after $1tn valuation call at Financial Times
09:51AM  Bank Of America Believes Shares Of Amgen Are Fairly Valued
09:12AM  Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology at noodls
09:04AM  Big Pharma But Not Such Big Money at Forbes
09:00AM  Amgen To Webcast Investor Call At the 73rd Annual Meeting of the American Academy of Dermatology PR Newswire
07:00AM  Actavis' Wide-Moat Transformation Offers Shareholder Rewards at Morningstar
Mar-20-15 06:39PM  6 trades on surging biotech sector at CNBC
05:00PM  Judge rejects Amgen bid to stop biosimilar drug at bizjournals.com
05:00PM  Big biotech plays: 6 hot trades
04:32PM  Give Gilead Credit for Surge in Biotech Margins at Barrons.com
04:27PM  Biotech bulls take charge
01:01PM  Booming biotech stocks: REGN, CELG & more
12:20PM  Amgen Loses Bid to Block a Biosimilar Version of its Best-Selling Drug at The Wall Street Journal
11:59AM  Biogen Boosts Biotech ETFs to More New Highs ETF Trends
09:11AM  Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan at noodls
09:00AM  Amgen Submits Application For Investigational LDL Cholesterol-Lowering Medication Repatha (evolocumab) In Japan PR Newswire
12:14AM  New Type of Cholesterol Drug Could Prove Costly at The Wall Street Journal
Mar-19-15 09:38PM  Price Concerns Follow News About Cholesterol Drug at The Wall Street Journal
06:31PM  Judge rejects Amgen request to block Sandoz's copycat drug at Los Angeles Times
06:22PM  Cramer: Snap up this incredible opportunity at CNBC
06:16PM  Judge Denies Amgen's Request to Block Novartis's Biosimilar of Neupogen at The Wall Street Journal
06:15PM  Esperion Therapeutics' fight against bad cholesterol
06:00PM  Biotech Stocks Extend Gains On Good Drug News at Investor's Business Daily
05:06PM  CEO of Sothebys Resigns amid Activist Pressure from Third Point
04:53PM  Novartis Wins Judges Approval to Sell First-of-Kind Copycat at Bloomberg
03:55PM  U.S. judge rejects Amgen bid to block biosimilar Neupogen
03:19PM  U.S. judge rejects Amgen injunction bid against Novartis Sandoz unit
02:36PM  Juno Therapeutics Comments On Cancer Cure Lifts Group at Investor's Business Daily
12:02PM  Consensus on the Street after Yellen
11:52AM  Cramer -- Biotech Excitement Continues, Retail Is All Over the Map at TheStreet
10:59AM  Why Biogen Deserves a Higher Valuation at Barrons.com
09:30AM  The Zacks Analyst Blog Highlights: Amgen, Regeneron, Nektar, ACADIA and Pharmacyclics - Press Releases
Mar-18-15 08:22PM  Hot Biotech Juno Therapeutics Burning Through Cash at Investor's Business Daily
05:10PM  Juno stock drops as company projects up to $150M in cash burn in first post-IPO report at bizjournals.com
05:10PM  State gives $19M in tax breaks to life science firms who will add 1,075 new jobs at bizjournals.com
04:30PM  Biotech Bull Market: The Two Best Ways to Play It at Barrons.com
03:45PM  Investors Relieved? Akorn Stock Retakes 50-Day Line at Investor's Business Daily
02:47PM  Esperion Soars on Positive Phase IIb Data on ETC-1002 - Analyst Blog
02:23PM  Midday Glance: Biotechnology companies
10:50AM  Regeneron Hits a 52-Week High on Positive Praluent Data - Analyst Blog
10:49AM  Biotech Stock Roundup: Amgen & Regeneron Shine at ACC, Nektar Drug Disappoints - Analyst Blog
Mar-17-15 10:46PM  Is This a Megablockbuster Drug in the Making? at Investopedia
05:05PM  Understanding Johnson & Johnsons Growth Strategies
04:43PM  Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology at noodls
04:01PM  Amgen To Present 10 Abstracts From Its Dermatology Portfolio At The 73rd Annual Meeting Of The American Academy Of Dermatology PR Newswire
11:39AM  Sanofi Upgraded On FX, Cholesterol Drug Promise at Investor's Business Daily
11:35AM  Kentucky joins lawsuit against Omnicare, claiming billions in losses at bizjournals.com
10:38AM  Amgen Gives Update Regarding Drug Trials
10:26AM  Esperion CEO Twitter Trolls His Larger, Cholesterol-Lowering Rivals at TheStreet
06:05AM  Jim Cramer on Biotech Stocks the Market Always Seems to Undervalue at TheStreet
Mar-16-15 08:28PM  Top Stock Regeneron Breaks Out On Big Drug News at Investor's Business Daily +5.69%
06:00PM  Cramer: Skepticism too thick
05:59PM  Regeneron/Sanofi's PCSK9 Drug Praluent Data Published - Analyst Blog
05:40PM  Nothing but net ... profits
05:37PM  Amgen, Regeneron Stocks Go Up As Drugs Bring Cholesterol Down at Forbes
05:03PM  Amgen Presents Encouraging PCSK9 Inhibitor Repatha Data - Analyst Blog
04:16PM  Stocks Close Sharply Higher As Health Care Leads at Investor's Business Daily
03:17PM  Amgen, other drug company shares jump on cholesterol drug findings at MarketWatch
03:01PM  Amgen: Looking for a Wild Card at Barrons.com
01:44PM  New Cholesterol Drugs may Reduce Heart Risks, But Final Results Aren't In at The Wall Street Journal
12:56PM  Top 2nd-half trades: Disney & health care
11:04AM  Cramer: 'Remarkable' Data From Regeneron, Amgen; Sees Edward Lifesciences Going Higher at TheStreet
09:30AM  Zacks Investment Ideas feature highlights: Biogen, Amgen, SPDR S&P Biotech ETF, BioShares Biotechnology Clinical Trials Fund and ProShares Ultra Nasdaq Biotechnology ETF - Press Releases
09:23AM  Cramer's Mad Dash: Regeneron breaking out
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine. The company's principal products include Neulasta, a pegylated protein to decrease the incidence of infection associated with chemotherapy-induced febrile neutropenia in cancer patients; NEUPOGEN, a recombinant-methionyl human granulocyte colony-stimulating factor for reducing the incidence of infection as manifested by febrile neutropenia for patients with non-myeloid malignancies; and Enbrel to treat rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis in adult patients. Its principal products also comprise EPOGEN for the treatment of dialysis; Aranesp for treating anemia; XGEVA for the prevention of skeletal-related events; Prolia to treat postmenopausal women with osteoporosis; and Sensipar/Mimpara products for use in the treatment of secondary hyperparathyroidism in chronic kidney disease patients on dialysis. The company's other marketed products include Kyprolis, a proteasome inhibitor to treat patients with multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound; Vectibix, a human monoclonal antibody; and BLINCYTO for the treatment of patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. It also develops various products that are in various clinical trials. The company serves pharmaceutical wholesale distributors; and healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. It has collaborative agreements with AstraZeneca Plc; Takeda Pharmaceutical Company Limited; UCB; and Bayer HealthCare Pharmaceuticals Inc. The company was founded in 1980 and is headquartered in Thousand Oaks, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tross Stuart ASVP, Human ResourcesMar 03Sale157.744,415696,42720,237Mar 04 08:25 PM
BALTIMORE DAVIDDirectorMar 02Sale158.763,647579,01131,159Mar 03 08:55 PM
BALTIMORE DAVIDDirectorFeb 19Option Exercise42.135,000210,65036,159Feb 23 04:13 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Option Exercise42.1384,0003,538,920258,641Feb 12 09:09 PM
Bradway Robert AChairman, CEO and PresidentFeb 11Sale152.6922,0003,359,116218,102Feb 12 09:09 PM
COFFMAN VANCE DDirectorFeb 06Option Exercise42.135,000210,65038,460Feb 06 06:23 PM
HERRINGER FRANK CDirectorFeb 05Option Exercise42.135,000210,65025,449Feb 05 08:11 PM
HERRINGER FRANK CDirectorFeb 05Buy152.293,000456,8702,000Feb 05 08:11 PM
de Carbonnel FrancoisDirectorDec 03Sale168.013,000504,04119,159Dec 03 05:00 PM
COFFMAN VANCE DDirectorSep 05Option Exercise56.7920,0001,135,80041,623Sep 09 06:54 PM
Harper Sean EEVP, Research & DevelopmentAug 05Sale127.2914,0001,782,12659,503Aug 07 04:22 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Option Exercise56.644,130233,91122,719May 22 05:15 PM
Dittrich Thomas J.W.VP, Finance & CAOMay 21Sale112.834,130465,98418,589May 22 05:15 PM
Bradway Robert AChairman, CEO and PresidentMay 12Buy111.7789499,919185,013May 12 08:33 PM
Michael A KellyActing CFOApr 28Sale110.452,065228,07241,041Apr 29 05:48 PM